Osteoporosis is a systemic skeletal disease characterized by low bone mass and deterioration of bone microarchitecture, leading to increased bone fragility and susceptibility to fracture. The primary goal of pharmacological intervention is to restore or preserve bone mechanical strength, thereby reducing the risk of fragility fractures. While bone mineral density (BMD) remains a key clinical surrogate, the mechanical integrity of bone depends on a complex interplay of material properties, microarchitecture, and bone turnover dynamics. This article reviews the mechanisms by which approved pharmacological treatments influence the mechanical strength of osteoporotic bone, drawing on preclinical biomechanical studies and clinical evidence.

Bone Mechanical Strength: What Matters Beyond Density

Bone mechanical strength is the ability of bone tissue to resist deformation and fracture under applied loads. It is determined by two broad categories: bone quantity (mass and density) and bone quality (architecture, material composition, and turnover). Osteoporosis degrades both. Cancellous bone loses trabecular connectivity and thickness; cortical bone becomes porous and thin. Material properties such as collagen cross-linking, mineral crystal size, and microdamage accumulation also change. Pharmacological treatments can affect these parameters in distinct ways. For instance, antiresorptive agents primarily preserve existing structure and reduce remodeling space, while anabolic agents can rebuild lost trabecular networks and increase cortical thickness. Understanding these mechanistic differences is essential for selecting therapies and interpreting outcomes beyond BMD.

Pharmacological Classes and Their Effects on Bone Mechanics

Bisphosphonates

Bisphosphonates, including alendronate, risedronate, zoledronic acid, and ibandronate, are the most widely prescribed antiresorptive agents. They inhibit osteoclast-mediated bone resorption by binding to hydroxyapatite and interfering with the mevalonate pathway. Randomized controlled trials have consistently demonstrated reductions in vertebral and nonvertebral fractures. Mechanically, bisphosphonates increase BMD and preserve trabecular architecture. Preclinical studies using animal models of ovariectomy-induced osteoporosis show that bisphosphonate treatment maintains or improves vertebral and femoral neck strength in compression and bending tests. For example, zoledronic acid has been shown to increase the ultimate load and stiffness of vertebral bodies in cynomolgus monkeys. However, prolonged use (especially >3–5 years) has raised concerns about atypical femoral fractures and osteonecrosis of the jaw, suggesting that over-suppression of remodeling may impair the bone’s ability to repair microdamage, degrading toughness over time. Nevertheless, for most patients, the net effect on mechanical strength is favorable when used within guideline-recommended durations. A meta-analysis of bisphosphonate trials confirms significant fracture risk reduction.

Denosumab

Denosumab is a human monoclonal antibody against RANKL, a key cytokine for osteoclast differentiation, activation, and survival. By blocking RANKL, it powerfully suppresses bone resorption. In the FREEDOM trial, denosumab reduced vertebral, hip, and nonvertebral fractures. Biomechanically, denosumab increases BMD at cortical and trabecular sites and improves estimated bone strength as assessed by finite element analysis of hip CT scans. In preclinical models, denosumab treatment increased vertebral compressive strength and femoral neck strength relative to vehicle controls. Animal studies also indicate that while denosumab increases cortical thickness and bone volume, it may reduce cortical porosity. This could enhance stiffness and ultimate strength. However, as with bisphosphonates, the very low bone turnover induced by denosumab raises theoretical concerns about microdamage accumulation. Notably, after discontinuation, a rapid rebound in bone resorption occurs, with increased vertebral fracture risk. Therefore, continuous treatment is required to maintain mechanical strength gains. The FREEDOM extension data demonstrate sustained fracture reduction over 10 years with appropriate transitioning.

Selective Estrogen Receptor Modulators (SERMs)

SERMs such as raloxifene and bazedoxifene act as estrogen agonists on bone while antagonizing estrogen receptors in breast and uterus. They reduce bone resorption and preserve bone mass. Raloxifene reduces vertebral fractures but does not significantly reduce nonvertebral fractures. From a mechanical perspective, SERMs improve trabecular microarchitecture and bone material properties in preclinical studies. Ovariectomized rats treated with raloxifene showed improved vertebral compressive strength and femoral neck strength compared to untreated controls. However, the magnitude of strength improvement appears smaller than that seen with bisphosphonates or denosumab, likely due to a more moderate antiresorptive effect. SERMs may also positively influence bone material quality by maintaining collagen cross-linking and reducing matrix mineralization heterogeneity. Their role in combination or sequential therapy is still under investigation.

Anabolic Agents: Teriparatide and Abaloparatide

Teriparatide (recombinant human PTH 1-34) and abaloparatide (a PTHrP analog) are osteoanabolic agents that stimulate bone formation when administered daily at low doses. They increase bone mass by promoting osteoblast activity, leading to thicker trabeculae, improved trabecular connectivity, and increased cortical thickness. Biomechanical studies in animals show marked increases in vertebral and femoral strength. For instance, teriparatide-treated ovariectomized rats exhibited up to 40% higher maximum load and energy to failure in lumbar vertebrae. In humans, teriparatide improves BMD and reduces vertebral and nonvertebral fractures. Finite element analyses of hip CT scans show significant improvements in estimated failure load and stiffness, especially at the femoral neck. Importantly, anabolic agents improve not only bone quantity but also bone quality. They enhance the distribution of bone material, increasing the moment of inertia and cross-sectional area. The net effect is a bone that is both denser and architecturally superior. However, the duration of anabolic therapy is limited to 2 years due to the theoretical risk of osteosarcoma in animal studies, though this has not been observed in human clinical use. The VERO trial demonstrated superior vertebral fracture reduction with teriparatide versus risedronate.

Romosozumab: A Dual-Agent Approach

Romosozumab is a monoclonal antibody against sclerostin, a Wnt pathway inhibitor. It simultaneously increases bone formation and decreases bone resorption, a unique dual effect. In clinical trials (FRAME, ARCH), romosozumab rapidly increased BMD and reduced vertebral, hip, and nonvertebral fractures. Preclinical studies in rats and nonhuman primates show that romosozumab dramatically increases bone mass, trabecular thickness, and cortical bone formation, resulting in impressive gains in mechanical strength. For example, ovariectomized rats treated with romosozumab for 12 weeks showed vertebral ultimate load and stiffness significantly greater than controls and comparable to or exceeding baseline. Finite element modeling from densitometry data in the ARCH trial indicated that romosozumab improved hip strength parameters more than alendronate. The combination of increased formation and reduced resorption yields a bone with better material and structural properties, though long-term safety data are still accumulating. Romosozumab is typically used for one year, followed by an antiresorptive. The ARCH trial data show sustained fracture reduction after transitioning to denosumab.

Impact on Bone Microarchitecture and Material Properties

Beyond BMD, all osteoporosis treatments affect bone microarchitecture and material composition. Antiresorptives preserve existing trabecular structure, reducing perforations and maintaining connectivity. Anabolic agents can actually restore lost trabecular structure, increasing trabecular number and thickness. Material properties include the degree of mineralization, collagen cross-linking, and microdamage. Antiresorptives increase mean mineralization density by allowing more complete secondary mineralization, which increases stiffness but may reduce toughness. Anabolic agents produce a more heterogeneous mineralization pattern that may improve energy absorption. Romosozumab, due to its dual action, may achieve a favorable balance. Preclinical studies using micro-CT and histological analysis confirm that treatment-specific changes in bone volume fraction, trabecular thickness, cortical porosity, and collagen maturity correlate with biomechanical outcomes. For instance, a study on zoledronic acid in osteoporotic sheep showed increased bone volume and trabecular thickness, with corresponding increases in ultimate stress and toughness. The challenge remains to translate these microarchitectural improvements directly into clinical fracture risk prediction, but they provide mechanistic rationale for observed efficacy.

Clinical Implications and Fracture Risk Reduction

The ultimate measure of pharmacological impact on bone mechanical strength is reduction in fracture incidence. Randomized trials show that all approved agents reduce vertebral fractures; hip and nonvertebral fracture reduction varies by drug class. Anabolic agents and romosozumab appear to achieve more rapid and substantial fracture reduction in high-risk patients. Treatment selection should therefore consider baseline fracture risk, BMD, age, renal function, and patient preference. In clinical practice, monitoring response via BMD or bone turnover markers can confirm expected mechanical gains. It is important that treatment be continued without gaps to sustain mechanical strength improvements. For patients on denosumab, transitioning to another antiresorptive (e.g., bisphosphonate) after a planned break might mitigate rebound bone loss and protect strength. Similarly, after anabolic therapy, a course of antiresorptive therapy is necessary to preserve newly formed bone. Clinicians should also consider that some agents, like bisphosphonates, have persistence in bone matrix and may confer residual mechanical protection even after discontinuation, whereas others, like denosumab, do not. The concept of “drug holiday” for bisphosphonates after 3–5 years is supported by data showing maintained fracture reduction, likely due to stored drug and sustained reduction in remodeling space.

Future Directions

Ongoing research aims to develop new agents that further uncouple bone resorption and formation. Cathepsin K inhibitors (e.g., odanacatib) showed potent antiresorptive efficacy but raised cardiovascular safety concerns. Agents targeting the Wnt pathway, such as small molecule inhibitors of sclerostin, are in development. Combination therapy with anabolic and antiresorptive agents is being explored to optimize mechanical strength gains. Furthermore, advanced imaging techniques like high-resolution peripheral quantitative CT (HR-pQCT) and finite element analysis are being validated to assess bone mechanical properties noninvasively. These tools may eventually guide individualized treatment selection and monitoring. Another promising area is the investigation of bone material properties through Raman spectroscopy and nanoindentation to detect early changes in collagen and mineral quality in response to therapy. Such approaches could help tailor treatments to improve not just density but true fracture resistance.

Conclusion

Pharmacological treatments for osteoporosis—bisphosphonates, denosumab, SERMs, teriparatide, abaloparatide, and romosozumab—exert distinct effects on bone mechanical strength. Antiresorptive agents preserve existing bone mass and architecture, improving stiffness and ultimate load, while anabolic agents rebuild bone, enhancing both structural and material properties. Romosozumab combines the benefits of both. Clinical trials confirm substantial fracture risk reduction, with the magnitude and speed depending on the agent and the skeletal site. The future of osteoporosis management will likely involve personalized sequencing of therapies guided by assessment of bone mechanical strength beyond BMD alone. By understanding how each class modifies the biomechanical profile of bone, clinicians can make more informed decisions to prevent fragility fractures and improve patient outcomes.